

Substitute Form PTO-1449 (Modified)		U.S. Department of Commerce Patent and Trademark Office	Attorney Docket No. 14875-0164US1	Application No. 10/582,413
<b>Information Disclosure Statement by Applicant</b> (Use several sheets if necessary)  (37 CFR §1.98(b))		Applicant Toshihiko Ohtomo <i>et al.</i>		
		Filing Date October 26, 2006	Group Art Unit 1643	

<b>U.S. Patent Documents</b>							
Examiner Initial	Desig. ID	Document Number	Publication Date	Patentee	Class	Subclass	Filing Date If Appropriate
/BD/	1	4,946,778	08/1990	Ladner <i>et al.</i>			
	2	5,789,554	08/1998	Leung <i>et al.</i>			
	3	5,837,242	11/1998	Holliger <i>et al.</i>			
	4	5,840,344	11/1998	Fukushima			
	5	5,885,574	03/1999	Elliott			
	6	6,126,980	10/2000	Smith <i>et al.</i>			
	7	6,579,692	06/2003	Fukushima			
	8	6,719,972	04/2004	Gribben <i>et al.</i>			
	9	6,759,043	07/2004	Fukushima			
	10	7,115,373	10/2006	Hashida <i>et al.</i>			
	11	7,456,260	11/2008	Rybak <i>et al.</i>			
	12	2003/0147894	08/2003	Fukushima <i>et al.</i>			
	13	2003/0157100	08/2003	Fukushima <i>et al.</i>			
	14	2003/0157577	08/2003	Fukushima <i>et al.</i>			
	15	2003/0202975	10/2003	Tedder			
	16	2003/0211108	11/2003	Fukushima <i>et al.</i>			
	17	2004/0001828	01/2004	Tuscano <i>et al.</i>			
	18	2004/0073013	04/2004	Fukushima <i>et al.</i>			
	19	2008/0248037	10/2008	Li <i>et al.</i>			
	20	2009/0022687	01/2009	Matsumoto <i>et al.</i>			
	21	2009/0028854	01/2009	Igawa <i>et al.</i>			
↓	22	2009/0117097	05/2009	Igawa <i>et al.</i>			

<b>Foreign Patent Documents or Published Foreign Patent Applications</b>							
Examiner Initial	Desig. ID	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation Yes      No
/BD/	23	EP 0 721 015	07/10/1996	Europe			
/BD/	24	EP 1 035 132	09/13/2000	Europe			

Examiner Signature /Brad Duffy/	Date Considered 01/11/2010
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Substitute Form PTO-1449 (Modified)		U.S. Department of Commerce Patent and Trademark Office	Attorney Docket No. 14875-0164US1	Application No. 10/582,413
<b>Information Disclosure Statement by Applicant</b> (Use several sheets if necessary)  (37 CFR §1.98(b))		Applicant Toshihiko Ohtomo <i>et al.</i>		
		Filing Date October 26, 2006	Group Art Unit 1643	

<b>Foreign Patent Documents or Published Foreign Patent Applications</b>							
Examiner Initial	Desig. ID	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation
							Yes      No
/BD/	25	EP 1 327 681	07/16/2003	Europe			
	26	EP 1 396 500	03/10/2004	Europe			
	27	EP 1 262 548	08/10/2008	Europe			
	28	JP 7236475	09/12/1995	Japan			Abstract only
	29	JP 11-092500	04/06/1999	Japan			Abstract only
	30	JP 2000-95800	04/04/2000	Japan			Abstract only
	31	WO 91/16928	11/14/1991	WIPO			
	32	WO 92/19759	11/12/1992	WIPO			English abstract
	33	WO 94/13806	06/23/1994	WIPO			
	34	WO 96/36360	11/21/1996	WIPO			
	35	WO 97/01633	01/16/1997	WIPO			
	36	WO 97/32601	09/12/1997	WIPO			English abstract
	37	WO 98/44001	08/10/1998	WIPO			
	38	WO 99/12973	03/18/1999	WIPO			English abstract
	39	WO 99/17364	04/08/1999	WIPO			
	40	WO00/53634	09/14/2000	WIPO			English abstract
	41	WO00/75191	12/14/2000	WIPO			
	42	WO01/77342	10/18/2001	WIPO			
	43	WO 01/87337	11/22/2001	WIPO			
	44	WO02/094880	11/28/2002	WIPO			English abstract
	45	WO 02/097033	12/05/2002	WIPO			
↓	46	WO 2004/003019	01/08/2004	WIPO			

Examiner Signature  /Brad Duffy/	Date Considered  01/11/2010
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Substitute Form PTO-1449 (Modified)		U.S. Department of Commerce Patent and Trademark Office	Attorney Docket No. 14875-0164US1	Application No. 10/582,413
<b>Information Disclosure Statement by Applicant</b> (Use several sheets if necessary)  (37 CFR §1.98(b))		Applicant Toshihiko Ohtomo <i>et al.</i>		
		Filing Date October 26, 2006	Group Art Unit 1643	

<b>Other Documents (include Author, Title, Date, and Place of Publication)</b>		
Examiner Initial	Desig. ID	Document
/BD/	47	ARNDT <i>et al.</i> , "Factors Influencing the Dimer to Monomer Transition of an Antibody Single-Chain Fv Fragment," <i>Biochemistry</i> , 37:12918-12926 (1998)
	48	AVENT <i>et al.</i> , "Monoclonal antibodies that recognize different membrane proteins that are deficient in Rhnull human erythrocytes. One group of antibodies reacts with a variety of cells and tissues whereas the other group is erythroid-specific," <i>Biochem. J.</i> , 251:499-505 (1988)
	49	BARTLEY <i>et al.</i> , "Identification and Cloning of a Megakaryocyte Growth and Development Factor That is a Ligand for the Cytokine Receptor Mpl," <i>Cell</i> , 77:1117-1124 (1994)
	50	BAZIL <i>et al.</i> , "Apoptosis of human hematopoietic progenitor cells induced by crosslinking of surface CD43, the major sialoglycoprotein of leukocytes," <i>Blood</i> , 86:502-511 (1995)
	51	BAZZONI <i>et al.</i> , "Chimeric tumor necrosis factor receptors with constitutive signaling activity," <i>Proc. Natl. Acad. Sci. USA</i> , 92(12):5376-5580 (1995)
	52	BERESFORD <i>et al.</i> , "Binding Characteristics and Tumor Targeting of a Covalently Linked Divalent CC49 Single-Chain Antibody," <i>Int. J. Cancer</i> , 81:911-917 (1999)
	53	BERGER <i>et al.</i> , "Inhibition of intractable nucleases with ribonucleoside-vanadyl complexes: isolation of messenger ribonucleic acid from resting lymphocytes," <i>Biochemistry</i> , 18(23):5143-5149 (1979)
	54	BODMER <i>et al.</i> , "TRAIL Receptor-2 Signals Apoptosis Through FADD and Caspase-8," <i>Nat. Cell Biol.</i> , 2:241-243 (2000)
	55	BORDEN <i>et al.</i> , "Lymphokines and Cytokines as Cancer Treatment," <i>Cancer</i> , 65:800-814 (1990)
	56	BOWIE <i>et al.</i> , "Deciphering the Message in Protein Sequences: Tolerance to Amino Acid Substitutions," <i>Science</i> , 247:1306-1310 (1990)
	57	BROWN <i>et al.</i> , "Integrin-associated protein: a 50-kD plasma membrane antigen physically and functionally associated with integrins," <i>J. Cell Biology</i> , 111(6 Pt 1):2785-2794 (1990)
	58	BROWN <i>et al.</i> , "Integrin-associated protein (CD47) and its ligands," <i>Trends Cell Biology</i> , 11(3):130-135 (2001)
	59	BUCHSBAUM <i>et al.</i> , "Antitumor Efficacy of TRA-8 Anti-DR5 Monoclonal Antibody Alone or in Combination with Chemotherapy and/or Radiation Therapy in a Human Breast Cancer Model," <i>Clin. Cancer Res.</i> , 9:3731-3741 (2003)
	60	BURGESS <i>et al.</i> , "Possible dissociation of the heparin-binding and mitogenic activities of heparin-binding (acidic fibroblast) growth factor-1 from its receptor-binding activities by site-directed mutagenesis of a single lysine residue," <i>J. Cell Biol.</i> , 111:2129-2138 (1990)
	61	BURTHEM <i>et al.</i> , "Hairy cell interactions with extracellular matrix: expression of specific integrin receptors and their role in the cell's response to specific adhesive proteins," <i>Blood</i> , 84(3):873-882 (1994)
	62	BYERS, "What Can Randomized Controlled Trials Tell us About Nutrition and Cancer Prevention?," <i>CA Cancer J. Clin.</i> , 49:353-361 (1999)
	63	CALDAS <i>et al.</i> , "Humanization of the anti-CD18 antibody 6.7: an unexpected effect of a framework residue in binding to antigen," <i>Mol. Immunol.</i> , 39:941-952 (2003)
↓	64	CARON <i>et al.</i> , "Engineered Humanized Dimeric Forms of IgG Are More Effective Antibodies," <i>J. Exp. Med.</i> , 176:1191-1195 (1992)

Examiner Signature <i>/Brad Duffy/</i>	Date Considered 01/11/2010
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Substitute Form PTO-1449 (Modified)		U.S. Department of Commerce Patent and Trademark Office	Attorney Docket No. 14875-0164US1	Application No. 10/582,413
<b>Information Disclosure Statement by Applicant</b> (Use several sheets if necessary)  (37 CFR §1.98(b))		Applicant Toshihiko Ohtomo <i>et al.</i>		
		Filing Date October 26, 2006	Group Art Unit 1643	

<b>Other Documents (include Author, Title, Date, and Place of Publication)</b>			
Examiner Initial	Desig. ID	Document	
/BD/	65	CHIEN <i>et al.</i> , "Significant structural and functional change of an antigen-binding site by a distant amino acid substitution: Proposal of a structural mechanism," <i>Proc. Natl. Acad. Sci. USA</i> , 86:5532-5536 (1989)	
	66	CHIRGWIN <i>et al.</i> , "Isolation of biologically active ribonucleic acid from sources enriched in ribonuclease," <i>Biochemistry</i> , 18(24):5294-5299 (1979)	
	67	CHUNTHARAPAI <i>et al.</i> "Isotype-Dependent Inhibition of Tumor Growth In Vivo by Monoclonal Antibodies to Death Receptor 4," <i>J. Immunol.</i> , 166:4891-4898 (2001)	
	68	COCHLOVIUS <i>et al.</i> , "Cure of Burkitt's Lymphoma in Severe Combined Immunodeficiency Mice by T Cells, Tetravalent CD3 x CD19 Tandem Diabody and CD28 Costimulation," <i>Cancer Res.</i> , 60:4336-4341 (2000)	
	69	COOPER <i>et al.</i> , "Transendothelial migration of neutrophils involves integrin-associated protein (CD47)," <i>Proc. Natl. Acad. Sci. USA</i> , 92:3978-3982 (1995)	
	70	DANIEL <i>et al.</i> , "Pathway of apoptosis induced in Jurkat T Lymphoblasts by anti-HLA Class I antibodies," <i>Human Immunology</i> , 65(3):189-199 (2004)	
	71	DE LEON <i>et al.</i> , "High resolution human leukocyte antigen (HLA) class I and class II allele typing in Mexican mestizo women with sporadic breast cancer: case-control study," <i>BMC Cancer</i> , 9(48):1-9 (2009)	
	72	DEGLI-ESPOSTI <i>et al.</i> , "Cloning and Characterization of TRAIL-R3, a Novel Member of the Emerging TRAIL Receptor Family," <i>J. Exp. Med.</i> , 186:1165-1170 (1997)	
	73	DE SAUVAGE <i>et al.</i> , "Stimulation of Megakaryocytopoiesis and Thrombopoiesis by the c-Mpl Ligand," <i>Nature</i> , 369:533-538 (1994)	
	74	DESPLANCQ <i>et al.</i> , "Multimerization behaviour of single chain Fv variants for the tumour-binding antibody B72.3," <i>Protein Engineering</i> , 7(8):1027-1033 (1994)	
	75	DE ST. GROTH <i>et al.</i> , "Production of Monoclonal Antibodies: Strategy and Tactics," <i>Journal of Immunological Methods</i> , 35:1-21 (1980)	
	76	DILLMAN, "Monoclonal antibodies for treating cancer," <i>Ann. Int. Med.</i> , 11(7):592-603 (1989)	
	77	DORAI <i>et al.</i> , "Mammalian cell expression of single-chain Fv (sFv) antibody proteins and their C-terminal fusions with interleukin-2 and other effector domains," <i>Biotechnology</i> , 12(9):890-897 (1994)	
	78	DUFNER <i>et al.</i> , "Harnessing phage and ribosome display for antibody optimization," <i>Trends Biotechnol.</i> , 24(11):523-529 (2006)	
	79	EMERY <i>et al.</i> , "Osteoprotegerin Is a Receptor for the Cytotoxic Ligand TRAIL," <i>J. Biol. Chem.</i> , 273:14363-14367 (1998)	
	80	FELGENHAUER <i>et al.</i> "Nucleotide Sequences of the cDNAs Encoding the V-Regions of H- and L-Chains of a Human Monoclonal Antibody Specific to HIV-1 - gp41," <i>Nucleic Acids Research</i> , 18(16):4927 (1990)	
	81	FUJIMOTO <i>et al.</i> , "50-kD integrin-associated protein does not detectably influence several functions of glycoprotein IIb-IIIa complex in human platelets," <i>Blood</i> , 86(6):2174-2182 (1995)	
	82	FUKUSHIMA <i>et al.</i> , "Enhanced hematopoiesis in vivo and in vitro by splenic stromal cells derived from the mouse with recombinant granulocyte colony-stimulating factor," <i>Blood</i> , 80(8):1914-1922 (1992)	
▼	83	FUKUSHIMA <i>et al.</i> , "Apoptosis of Bone Marrow Cells Via Integrin Associated Protein by the Novel Monoclonal Antibody," <i>Blood</i> , 94(10):479A (1999)	

Examiner Signature  /Brad Duffy/	Date Considered  01/11/2010
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Substitute Form PTO-1449 (Modified)		U.S. Department of Commerce Patent and Trademark Office	Attorney Docket No. 14875-0164US1	Application No. 10/582,413
<b>Information Disclosure Statement by Applicant</b> (Use several sheets if necessary)  (37 CFR §1.98(b))		Applicant Toshihiko Ohtomo <i>et al.</i>		
		Filing Date October 26, 2006	Group Art Unit 1643	

<b>Other Documents (include Author, Title, Date, and Place of Publication)</b>		
Examiner Initial	Desig. ID	Document
/BD/	84	GALFRE <i>et al.</i> , "Preparation of monoclonal antibodies: strategies and procedures," <i>Methods in Enzymology</i> , 73:3-46 (1981)
	85	GALFRE <i>et al.</i> , "Rat x rat hybrid myelomas and a monoclonal anti-Fd portion of mouse IgG," <i>Nature</i> , 277:131-133 (1979)
	86	GIUSTI <i>et al.</i> , "Somatic diversification of S107 from an antiphosphocholine to an anti-DNA autoantibody is due to a single base change in its heavy chain variable region," <i>Proc. Natl. Acad. Sci. USA</i> , 84:2926-2930 (1987)
	87	GODING, "Monoclonal Antibodies: Principles and Practice," <i>Academic Press</i> , second Ed., 125:129 (1986)
	88	GRANZIERO <i>et al.</i> , "Adoptive immunotherapy prevents prostate cancer in a transgenic animal model," <i>Eur. J. Immunol.</i> , 29:1127-1138 (1999)
	89	GREENSPAN <i>et al.</i> , "Defining epitopes: It's not as easy as it seems," <i>Nature Biotechnology</i> , 17:936-937 (1999)
	90	GRELL <i>et al.</i> , "TR60 and TR80 tumor necrosis factor (TNF)-receptors can independently mediate cytolysis," <i>Lymphokine and Cytokine Research</i> , 12(3):143-148 (1993)
	91	GRIFFITH <i>et al.</i> , "Functional Analysis of TRAIL Receptors Using Monoclonal Antibodies," <i>J. Immunol.</i> , 162:2597-2605 (1999)
	92	GÜSSOW and SEEMANN, "Humanization of Monoclonal Antibodies," <i>Methods in Enzymology</i> , 203:99-121 (1991)
	93	HOLLIGER <i>et al.</i> , "Specific Killing of Lymphoma Cells by Cytotoxic T-Cells Mediated by a Bispecific Diabody," <i>Protein Engineering</i> , 9(3):299-305 (1996)
	94	HOPP <i>et al.</i> , "A Short Polypeptide Marker Sequence Useful for Recombinant Protein Identification and Purification," <i>Biotechnology</i> , 6:1204-1210 (1988)
	95	HORAN <i>et al.</i> , "Dimerization of the extracellular domain of granulocyte-colony stimulating factor receptor by ligand binding: a monovalent ligand induces 2:2 complexes," <i>Biochemistry</i> , 35:4886-4896 (1996)
	96	HUSTON <i>et al.</i> , "Protein Engineering of Antibody Binding Sites: Recovery of Specific Activity in an Anti-Digoxin Single-Chain Fv Analogue Produced in <i>Escherichia Coli</i> ," <i>Proc. Natl. Acad. Sci. USA</i> , 85:5879-5883 (1988)
	97	ICHIKAWA <i>et al.</i> , "Tumoricidal activity of a novel anti-human DR5 monoclonal antibody without hepatocyte cytotoxicity," <i>Nat. Med.</i> , 7:954-960 (2001)
	98	ITOH <i>et al.</i> , "The Polypeptide Encoded by the cDNA for Human Cell Surface Antigen Fas Can Mediate Apoptosis," <i>Cell</i> , 66:233-243 (1991)
	99	JONES <i>et al.</i> , "Rapid PCR-Cloning of Full-Length Mouse Immunoglobulin Variable Regions," <i>Biotechnology</i> , 9:88-89 (1991)
	100	KEARNEY, <i>et al.</i> , "A New Mouse Myeloma Cell Line That Has Lost immunoglobulin Expression But Permits The Construction of Antibody-Secreting Hybrid Cells Lines," <i>The Journal of Immunology</i> , 123(4):1548-1550 (1979)
	101	KEEN <i>et al.</i> , "The use of serum-free medium for the production of functionally active humanized monoclonal antibody from NSO mouse myeloma cells engineered using glutamine synthetase as a selectable marker," <i>Cytotechnology</i> , 18(3):207-217 (Abstract) (1994)
▼	102	KIPRIYANOV <i>et al.</i> , "Bispecific CD3 x CD19 diabody for T cell-mediated lysis of malignant human B cells," <i>In. J. Cancer</i> , 77:763-772 (1998)

Examiner Signature  /Brad Duffy/	Date Considered  01/11/2010
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Substitute Form PTO-1449 (Modified)		U.S. Department of Commerce Patent and Trademark Office	Attorney Docket No. 14875-0164US1	Application No. 10/582,413
<b>Information Disclosure Statement by Applicant</b> (Use several sheets if necessary)  (37 CFR §1.98(b))		Applicant Toshihiko Ohtomo <i>et al.</i>		
		Filing Date October 26, 2006	Group Art Unit 1643	

<b>Other Documents (include Author, Title, Date, and Place of Publication)</b>			
Examiner Initial	Desig. ID	Document	
/BD/	103	KOHLER, <i>et al.</i> , "Derivation of specific antibody-producing tissue culture and tumor lines by cell fusion," <i>Eur. J. Immunol.</i> , 6:511-519 (1976)	
	104	KORTT <i>et al.</i> , "Recombinant anti-sialidase single-chain variable fragment antibody: Characterization, formation of dimer and higher-molecular-mass multimers and the solution of the crystal structure of the single-chain variable fragment/sialidase complex," <i>Eur. J. Biochem.</i> , 221:151-157 (1994)	
	105	KORTT <i>et al.</i> , "Single-chain Fv fragments of anti-neuraminidase antibody NC10 containing five- and ten-residue linkers form dimmers and with zero-residue linker a trimer," <i>Protein Engineering</i> , 10(4):423-433 (1997)	
	106	KOZAK, M., "At Least Six Nucleotides Preceding the AUG Initiator Codon Enhance Translation in Mammalian Cells," <i>J. Mol. Biol.</i> , 196:947-950 (1987)	
	107	KUMAR <i>et al.</i> , "Molecular cloning and expression of the fabs of human autoantibodies in <i>Escherichia coli</i> ," <i>The Journal of Biological Chemistry</i> , 275(41):35129-35136 (2000)	
	108	LARRICK, <i>et al.</i> , "Polymerase Chain Reaction Using Mixed Primers: Cloning of Human Monoclonal Antibody Variable Region Genes From Single Hybridoma Cells," <i>Biotechnology</i> , 7:934-938 (1989)	
	109	LAW <i>et al.</i> , "Observations On The Effect Of A Folic-Acid Anagonist On Transplantable Lymphoid Leukemias In Mice," <i>Journal of the National Cancer Institute</i> , 10:179-193 (1949)	
	110	LAZAR <i>et al.</i> , "Transforming growth factor $\alpha$ : mutation of aspartic acid 47 and leucine 48 results in different biological activities," <i>Molecular and Cellular Biology</i> , 8:1247-1252 (1988)	
	111	LEI <i>et al.</i> , "Characterization of the <i>Erwinia Carotovora pelB</i> Gene and Its Product Pectate Lyase," <i>Journal of Bacteriology</i> , 169:4379-4383 (1987)	
	112	LIN <i>et al.</i> , "Structure-function relationships in glucagon: properties of highly purified des-His-1-, monoiodo-, and (des-Asn-28, Thr-29)(homoserine lactone-27)-glucagon," <i>Biochemistry</i> , 14:1559-1563 (1975)	
	113	LINDBERG <i>et al.</i> , "Molecular Cloning of Integrin-Associated Protein: An Immunoglobulin Family Member with Multiple Membrane-Spanning Domains Implicated in $\alpha_v\beta_3$ -Dependent Ligand Binding," <i>The Journal of Cell Biology</i> , 123(2):485-496, The Rockefeller University Press (1993)	
	114	LINDBERG <i>et al.</i> , "Rh-Related Antigen CD47 is the Signal-Transducer Integrin-Associated Protein," <i>J. Biol. Chem.</i> , 269:1567-1570 (1994)	
	115	MARGULIES <i>et al.</i> , "Somatic Cell Hybridization of Mouse Myeloma Cells," <i>Cell</i> , 8:405-415 (1976)	
	116	MARIUZZA <i>et al.</i> , "The structural basis of antigen-antibody recognition," <i>Annu. Rev. Biophys. Biophys. Chem.</i> , 16:139-159 (1987)	
	117	MARSTERS <i>et al.</i> , "A Novel Receptor for Apo2L/TRAIL Contains a Truncated Death Domain," <i>Curr. Biol.</i> , 7:1003-1006 (1997)	
	118	MATEO <i>et al.</i> , "Induction of Apoptosis in B-Cells From Chronic Lymphocytic Leukemia (B-CLLs) by CD47," <i>FASEB Journal</i> , 12(5):A1082 (1998)	
	119	MATEO <i>et al.</i> , "CD47 ligation induces caspase-independent cell death in chronic lymphocytic leukemia," <i>Nat. Med.</i> , 5(11):1277-1284 (1999)	
↓	120	MAWBY <i>et al.</i> , "Isolation and characterization of CD47 glycoprotein: a multispanning membrane protein which is the same as integrin-associated protein (IAP) and the ovarian tumor marker OA3," <i>Biochem. J.</i> , 304:525-530 (1994)	

Examiner Signature  /Brad Duffy/	Date Considered  01/11/2010
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Substitute Form PTO-1449 (Modified)		U.S. Department of Commerce Patent and Trademark Office	Attorney Docket No. 14875-0164US1	Application No. 10/582,413
<b>Information Disclosure Statement by Applicant</b> (Use several sheets if necessary)  (37 CFR §1.98(b))		Applicant Toshihiko Ohtomo <i>et al.</i>		
		Filing Date October 26, 2006	Group Art Unit 1643	

<b>Other Documents (include Author, Title, Date, and Place of Publication)</b>		
Examiner Initial	Desig. ID	Document
/BD/	121	METHIA <i>et al.</i> , "Oligodeoxynucleotides Antisense to the Proto-Oncogene <i>c-Mpl</i> Specifically Inhibit In Vitro Megakaryocytopoiesis," <i>Blood</i> , 82(5):1395-1401 (1993)
	122	MILILI <i>et al.</i> , "The VDJ Repertoire Expressed in Human preB Cells Reflects the Selection of <i>Bona Fide</i> Heavy Chains," <i>Eur. J. Immunol.</i> , 26:63-69 (1996)
	123	MIZUSHIMA <i>et al.</i> , "pEF-BOS, a Powerful Mammalian Expression Vector," <i>Nucleic Acids Research</i> , 18(17):5322 (1990)
	124	MOORE <i>et al.</i> , "Kinetics and thermodynamics of dimer formation and dissociation for a recombinant humanized monoclonal antibody to vascular endothelial growth factor," <i>Biochemistry</i> , 38:13960-13967 (1999)
	125	MORI <i>et al.</i> , "Human normal hepatocytes are susceptible to apoptosis signal mediated by both TRAIL-R1 and TRAIL-R2," <i>Cell Death and Differentiation</i> , 11:203-207 (2004)
	126	MULLIGAN <i>et al.</i> , "Synthesis of Rabbit $\beta$ -Globin in Cultured Monkey Kidney Cells Following Infection with a SV40 $\beta$ -Globin Recombinant Genome," <i>Nature</i> , 277:108-114 (1979)
	127	NAKAYAMA <i>et al.</i> , "Thrombocytosis in preterm infants: a possible involvement of thrombopoietin receptor gene expression," <i>Journal of Molecular Medicine</i> , 83:316-320 (2005)
	128	NGO <i>et al.</i> , "Computational Complexity, Protein Structure Prediction, and the Levinthal Paradox," <i>The Protein Folding Problem and Tertiary Structure Prediction</i> , Merz, Jr. <i>et al.</i> Editors, Birkhauser Boston, 433-506 (1994)
	129	O'BRIEN <i>et al.</i> , "Monoclonal antibodies for the human insulin receptor stimulate intrinsic receptor-kinase activity," <i>Biochim. Soc. Trans.</i> , 14(6):1021-1023 (1986)
	130	OHTSUKA <i>et al.</i> , "Synergistic induction of tumor cell apoptosis by death receptor antibody and chemotherapy agent through JNK/p38 and mitochondrial death pathway," <i>Oncogene</i> , 22:2034-2044 (2003)
	131	PAN <i>et al.</i> , "An Antagonist Decoy Receptor and a Death Domain-Containing Receptor for TRAIL," <i>Science</i> , 277:815-818 (1997)
	132	PAN <i>et al.</i> , "The Receptor for the Cytotoxic Ligand TRAIL," <i>Science</i> , 276:111-113 (1997)
	133	PAUL, <i>Fundamental Immunology</i> , Raven Press, NY, Chapter 8, p. 242 (1993)
	134	PAUL, <i>Fundamental Immunology</i> , 3rd Edition, Raven Press, NY, Chapter 8, pp. 292-295 (1993)
	135	PETTERSON <i>et al.</i> , "CD47 Signals T Cell Death," <i>J. Immunol.</i> , 7031-7040 (1999)
	136	PETTERSON, "CD47 and death signaling in the immune system," <i>Apoptosis</i> , 5:299-306 (2000)
	137	REINHOLD <i>et al.</i> , "In vivo expression of alternatively spliced forms of integrin-associated protein (CD47)," <i>J. Cell Science</i> , 108:3419-3425 (1995)
	138	RIECHMANN <i>et al.</i> , "Reshaping Human Antibodies for Therapy," <i>Nature</i> , 332:323-327 (1988)
	139	REITER <i>et al.</i> , "Engineering interchain disulfide bonds into conserved framework regions of Fv fragments: improved biochemical characteristics of recombinant immunotoxins containing disulfide-stabilized Fv," <i>Protein Engineering</i> , 7(5):697-704 (1994)
	140	REITER <i>et al.</i> , "Stabilization of the Fv Fragments in Recombinant Immunotoxins by Disulfide Bonds Engineered into Conserved Framework Regions," <i>Biochemistry</i> , 33:5451-5459 (1994)
↓	141	ROUE <i>et al.</i> , "Mitochondrial dysfunction in CD47-mediated caspase-independent cell death: ROS production in the absence of cytochrome c and AIF release," <i>Biochimie</i> , 85:741-746 (2003)

Examiner Signature /Brad Duffy/	Date Considered 01/11/2010
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Substitute Form PTO-1449 (Modified)		U.S. Department of Commerce Patent and Trademark Office	Attorney Docket No. 14875-0164US1	Application No. 10/582,413
<b>Information Disclosure Statement by Applicant</b> (Use several sheets if necessary)  (37 CFR §1.98(b))		Applicant Toshihiko Ohtomo <i>et al.</i>		
		Filing Date October 26, 2006	Group Art Unit 1643	

<b>Other Documents (include Author, Title, Date, and Place of Publication)</b>			
Examiner Initial	Desig. ID	Document	
/BD/	142	ROZSNYAY <i>et al.</i> , "Phenylarsine oxide (PAO) blocks antigen receptor-induced calcium response and tyrosine phosphorylation of a distinct group of proteins," <i>Immunology Lett.</i> , 37(2-3):197-205 (1993)	
	143	SACKSTEIN, "The lymphocyte homing receptors: gatekeepers of the multistep paradigm," <i>Current Opinion in Hematology</i> , 12:444-450 (2005)	
	144	SATO <i>et al.</i> , "Reshaping a Human Antibody to Inhibit the Interleukin 6-Dependent Tumor Cell Growth," <i>Cancer Research</i> , 53:851-856 (1993)	
	145	SCHICKEL, <i>et al.</i> , "Gene for Integrin-Associated Protein (IAP, CD47): Physical Mapping, Genomic Structure, and Expression Studies in Skeletal Muscle," <i>Biochem. Cell. Biol.</i> , 80(2):169-176 (2002)	
	146	SCHWARTZ <i>et al.</i> , "A superactive insulin: [B10-aspartic acid]insulin(human)," <i>Proc. Natl. Acad. Sci. U.S.A.</i> , 84:6408-6411 (1987)	
	147	SCHWARTZ <i>et al.</i> , "A 50-kDa Integrin-associated Protein Is Required for Integrin-regulated Calcium Entry in endothelial Cells," <i>J. Biol. Chem.</i> , 268(27):19931-19934 (1993)	
	148	SCHMIDT <i>et al.</i> , "A bivalent single-chain antibody-toxin specific for ErbB-2 and the EGF receptor," <i>Int. J. Cancer</i> , 65(4):538-546 (1996)	
	149	SHERIDAN <i>et al.</i> , "Control of TRAIL-Induced Apoptosis by a Family of Signaling and Decoy Receptors," <i>Science</i> , 277:818-821 (1997)	
	150	SHIGETA <i>et al.</i> , "Sperm-immobilizing monoclonal antibody to human seminal plasma antigens," <i>Clin. Exp. Immunol.</i> , 42:458-462 (1980)	
	151	SHULMAN <i>et al.</i> , "A better cell line for making hybridomas secreting specific antibodies," <i>Nature</i> , 276:269-270 (1978)	
	152	SMITH-GILL <i>et al.</i> , "Contributions of immunoglobulin heavy and light chains to antibody specificity for lysozyme and two haptens," <i>The Journal of Immunology</i> , 139:4135-4144 (1987)	
	153	SONG <i>et al.</i> , "Light chain of natural antibody plays a dominant role in protein antigen binding," <i>Biochemical and Biophysical Research Communications</i> , 268:390-394 (2000)	
	154	SOUYRI, M., "Mpl: from an acute myeloproliferative virus to the isolation of the long sought thrombopoietin," <i>Seminars in Hematology</i> , 35(3):222-231 (1998)	
	155	SPAARGAREN <i>et al.</i> , "Antibody-induced Dimerization Activates the Epidermal Growth Factor Receptor Tyrosine Kinase," <i>The J. Biol. Chem.</i> , 266(3):1733-1739 (1981)	
	156	TROWBRIDGE, I.S., "Interspecies Spleen-Myeloma Hybrid Producing Monoclonal Antibodies Against Mouse Lymphocyte Surface Glycoprotein, T200," <i>J. Exp. Med.</i> , 148:313-323 (1978)	
	157	VAN GEELEN <i>et al.</i> , "Differential modulation of the TRAIL receptors and the CD95 receptor in colon carcinoma cell lines," <i>Br. J. Cancer</i> , 89(2):363-373 (2003)	
	158	VERMA <i>et al.</i> , "Antibody engineering: Comparison of bacterial, yeast, insect and mammalian expression systems," <i>Journal of Immunological Methods</i> , 216:165-181 (1998)	
	159	WAKALEE <i>et al.</i> , <i>Ann. Oncol.</i> On-line publication (7/24/2009)	
	160	WALCZAK <i>et al.</i> , "TRAIL-R2: A Novel Apoptosis-Mediating Receptor for TRAIL," <i>EMBO J.</i> , 16:5386-5397 (1997)	
	161	WARD <i>et al.</i> , "Binding activities of a repertoire of single immunoglobulin variable domains secreted from Escherichia coli," <i>Nature</i> , 341:544-546 (1989)	
	162	WELLS, "Perspectives in Biochemistry," <i>Biochemistry</i> , 29(37):8509-8517 (1990)	

Examiner Signature  /Brad Duffy/	Date Considered  01/11/2010
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Substitute Form PTO-1449 (Modified)		U.S. Department of Commerce Patent and Trademark Office	Attorney Docket No. 14875-0164US1	Application No. 10/582,413
<b>Information Disclosure Statement by Applicant</b> (Use several sheets if necessary)  (37 CFR §1.98(b))		Applicant Toshihiko Ohtomo <i>et al.</i>		
		Filing Date October 26, 2006	Group Art Unit 1643	

<b>Other Documents (include Author, Title, Date, and Place of Publication)</b>			
Examiner Initial	Desig. ID	Document	
/BD/	163	WHITLOW <i>et al.</i> , "Multivalent Fvs: characterization of single-chain Fv oligomers and preparation of a bispecific Fv," <i>Protein Eng.</i> , 7(8):1017-1026 (1994)	
	164	WILEY <i>et al.</i> , "Identification and Characterization of a New Member of the TNF Family that Induces Apoptosis," <i>Immunity</i> , 3:673-682 (1995)	
	165	WINKLER <i>et al.</i> , "Changing the Antigen Binding Specificity by Single Point Mutations of an Anti-p24 (HIV-1) Antibody," <i>J. Immunol.</i> , 265:4505-4514 (2000)	
	166	XIE <i>et al.</i> , "Direct Demonstration of MuSK Involvement in Acetylcholine Receptor Clustering Through Identification of Agonist ScFv," <i>Nature Biotechnology</i> , 15(8):768-771 (1997)	
	167	YAGITA <i>et al.</i> , "TRAIL and its receptors as targets for cancer therapy," <i>Cancer Sci.</i> , 95:777-783 (2004)	
	168	YANABU <i>et al.</i> , "Tyrosine phosphorylation and p72syk activation by an anti-glycoprotein lb monoclonal antibody," <i>Blood</i> , 89(5):1590-1598 (1997)	
	169	YARDEN <i>et al.</i> , "Self-phosphorylation of epidermal growth factor receptor: evidence for a model of intermolecular allosteric activation," <i>Biochemistry</i> , 26(5):1434-1442 (1987)	
	170	YELTON <i>et al.</i> , "Fusion of Mouse Myeloma and Spleen Cells," <i>Current Topics in Microbiology and Immunology</i> , 81:1-7 (1978)	
	171	U.S. EXAMINER ANNE GUSSOW, USPTO Restriction Requirement in U.S. App. Ser. No. 10/530,696, mailed October 19, 2006, 8 pages	
	172	FISH & RICHARDSON P.C., Response to Restriction Requirement dated October 19, 2006, in U.S. App. Ser. No. 10/530,696, filed November 16, 2006, 1 page	
	173	U.S. EXAMINER ANNE GUSSOW, USPTO Non-Final Office Action in U.S. App. Ser. No. 10/530,696, mailed December 21, 2006, 19 pages	
	174	FISH & RICHARDSON P.C., Amendment in Reply to Office Action dated December 21, 2006 in U.S. App. Ser. No. 10/530,696, filed April 23, 2007, 16 pages	
	175	U.S. EXAMINER ANNE GUSSOW, USPTO Final Office Action in U.S. App. Ser. No. 10/530,696, mailed August 8, 2007, 13 pages	
	176	U.S. EXAMINER ANNE GUSSOW, USPTO Interview Summary in U.S. App. Ser. No. 10/530,696, mailed November 26, 2007, 3 pages	
	177	FISH & RICHARDSON P.C., Amendment in Reply to Office Action dated August 8, 2007 in U.S. App. Ser. No. 10/530,696, filed December 6, 2007, 12 pages	
	178	U.S. EXAMINER ANNE GUSSOW, USPTO Advisory Action in U.S. App. Ser. No. 10/530,696, mailed December 14, 2007, 3 pages	
	179	U.S. EXAMINER ANNE GUSSOW, USPTO Non-Final Office Action in U.S. App. Ser. No. 10/530,696, mailed February 5, 2008, 9 pages	
	180	FISH & RICHARDSON, Amendment in Reply to Action dated February 5, 2008 in U.S. App. Ser. No. 10/530,696, filed August 5, 2008, 7 pages	
	181	U.S. EXAMINER ANNE GUSSOW, USPTO Non-Final Office Action in U.S. App. Ser. No. 10/530,696, mailed November 17, 2008, 18 pages	
	182	FISH & RICHARDSON, Amendment in Reply to Action dated November 17, 2008 in U.S. App. Ser. No. 10/530,696, filed February 17, 2009, 14 pages	
↓	183	JAPANESE PATENT OFFICE, International Search Report for App. Ser. No. PCT/JP2003/015063, mailed November 18, 2003, 2 pages	

Examiner Signature /Brad Duffy/	Date Considered 01/11/2010
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Substitute Form PTO-1449 (Modified)		U.S. Department of Commerce Patent and Trademark Office	Attorney Docket No. 14875-0164US1	Application No. 10/582,413
<b>Information Disclosure Statement by Applicant</b> (Use several sheets if necessary)  (37 CFR §1.98(b))		Applicant Toshihiko Ohtomo <i>et al.</i>		
		Filing Date October 26, 2006	Group Art Unit 1643	

<b>Other Documents (include Author, Title, Date, and Place of Publication)</b>			
Examiner Initial	Desig. ID	Document	
/BD/	184	JAPANESE PATENT OFFICE, International Preliminary Report on Patentability for App. Ser. No. PCT/JP2003/013063, dated February 6, 2004, 4 pages	
	185	EPO EXAMINER W. BERNHARDT, European Search Report for App. Ser. No. EP 03 75 1456, dated April 4, 2006, 2 pages	
	186	U.S. EXAMINER ANNE GUSSOW, USPTO Final Office Action in U.S. App. Ser. No. 10/530,696, mailed June 8, 2009, 10 pages	
	187	U.S. EXAMINER SHULAMITH H. SHAFFER, USPTO Restriction Requirement in U.S. App. Ser. No. 10/548,727, mailed April 12, 2007, 6 pages	
	188	FISH & RICHARDSON P.C., Reply to Restriction Requirement dated April 12, 2007 in U.S. App. Ser. No. 10/548,727, filed May 3, 2007, 1 page	
	189	U.S. EXAMINER SHULAMITH H. SHAFFER, USPTO Non-Final Office Action in U.S. App. Ser. No. 10/548,727, mailed August 3, 2007, 21 pages	
	190	FISH & RICHARDSON P.C. Reply to Office Action dated August 3, 2007 in U.S. App. Ser. No. 10/548,727, filed January 15, 2008, 15 pages	
	191	U.S. EXAMINER SHULAMITH H. SHAFFER, USPTO Final Office Action in U.S. App. Ser. No. 10/548,727, mailed April 29, 2008, 23 pages	
	192	U.S. EXAMINER SHULAMITH H. SHAFFER, USPTO Advisory Action in U.S. App. Ser. No. 10/548,727, mailed September 24, 2008, 6 pages	
	193	U.S. EXAMINER SHULAMITH H. SHAFFER, USPTO Non-Final Office Action in U.S. App. Ser. No. 10/548,727, mailed January 28, 2009, 16 pages	
	194	FISH & RICHARDSON P.C., Reply to Office Action dated January 28, 2009 in U.S. App. Ser. No. 10/548,727, filed June 26, 2009, 9 pages	
	195	JAPANESE PATENT OFFICE, International Search Report for App. Ser. No. PCT/JP2004/003334, mailed June 15, 2004, 3 pages	
	196	JAPANESE PATENT OFFICE, International Preliminary Report on Patentability for App. Ser. No. PCT/JP2004/003334, dated May 2, 2005, 6 pages	
	197	U.S. EXAMINER ANNE GUSSOW, USPTO Restriction Requirement in U.S. App. Ser. No. 10/550,934, mailed November 21, 2007, 7 pages	
	198	FISH & RICHARDSON P.C., Response to Restriction Requirement dated November 21, 2007 in U.S. App. Ser. No. 10/550,934, filed April 16, 2008, 2 pages	
	199	U.S. EXAMINER ANNE GUSSOW, USPTO Non-Final Office Action in U.S. App. Ser. No. 10/550,934, mailed June 12, 2008, 27 pages	
	200	FISH & RICHARDSON P.C., Amendment in Reply to Action dated June 12, 2008 in U.S. App. Ser. No. 10/550,934, filed December 12, 2008, 45 pages	
	201	U.S. EXAMINER ANNE GUSSOW, USPTO Final Office Action in U.S. App. Ser. No. 10/550,934, mailed March 16, 2009, 19 pages	
	202	FISH & RICHARDSON P.C., Amendment in Reply to Action dated March 16, 2009 in U.S. App. Ser. No. 10/550,934, filed September 10, 2009, 75 pages	
	203	JAPANESE PATENT OFFICE, International Search Report for App. Ser. No. PCT/JP2004/004696, mailed July 27, 2004, 5 pages	
↓	204	JAPANESE PATENT OFFICE, International Preliminary Report on Patentability for App. Ser. No. PCT/JP2004/004696, dated February 9, 2005, 10 pages	

Examiner Signature  /Brad Duffy/	Date Considered  01/11/2010
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Substitute Form PTO-1449 (Modified)		U.S. Department of Commerce Patent and Trademark Office	Attorney Docket No. 14875-0164US1	Application No. 10/582,413
<b>Information Disclosure Statement by Applicant</b> (Use several sheets if necessary)  (37 CFR §1.98(b))		Applicant Toshihiko Ohtomo <i>et al.</i>		
		Filing Date October 26, 2006	Group Art Unit 1643	

<b>Other Documents (include Author, Title, Date, and Place of Publication)</b>		
Examiner Initial	Desig. ID	Document
/BD/	205	EPO EXAMINER N. FAVRE, European Search Report for App. Ser. No. EP 04 72 4770, dated March 31, 2006, 4 pages
	206	U.S. EXAMINER LORRAINE SPECTOR, USPTO Restriction Requirement in U.S. App. Ser. No. 10/551,504, mailed June 27, 2008, 6 pages
	207	FISH & RICHARDSON P.C., Response to Restriction Requirement dated June 27, 2008 in U.S. App. Ser. No. 10/551,504, filed September 29, 2008, 13 pages
	208	U.S. EXAMINER LORRAINE SPECTOR, USPTO Restriction Requirement in U.S. App. Ser. No. 10/551,504, mailed December 16, 2008, 5 pages
	209	FISH & RICHARDSON P.C., Response to Restriction Requirement dated December 16, 2008 in U.S. App. Ser. No. 10/551,504, filed December 23, 2008, 14 pages
	210	U.S. EXAMINER LORRAINE SPECTOR, USPTO Non-Final Office Action in U.S. App. Ser. No. 10/551,504, mailed April 15, 2009, 35 pages
	211	FISH & RICHARDSON P.C., Amendment in Reply to Action dated April 15, 2009 in U.S. App. Ser. No. 10/551,504, filed August 14, 2009, 19 pages
	212	JAPANESE PATENT OFFICE, International Search Report for App. Ser. No. PCT/JP2004/018506, mailed March 22, 2005, 3 pages
	213	JAPANESE EXAMINER YOSHIKO KUWAHARA, International Preliminary Report on Patentability for App. Ser. No. PCT/JP2004/018506, 8 pages
	214	EPO EXAMINER ROBERT RANKIN, European Search Report for App. Ser. No. EP 04 82 0316, dated July 17, 2008, 3 pages
	215	JAPANESE PATENT OFFICE, International Search Report for App. Ser. No. PCT/JP2004/018499, mailed January 18, 2005, 2 pages
	216	JAPANESE PATENT OFFICE, International Preliminary Report on Patentability for App. Ser. No. PCT/JP2004/018499, dated January 26, 2006, 5 pages
	217	U.S. EXAMINER ANNE GUSSOW, USPTO Restriction Requirement in U.S. App. Ser. No. 10/582,304, mailed November 20, 2008, 7 pages
	218	FISH & RICHARDSON P.C., Response to Restriction Requirement dated November 20, 2008 in U.S. App. Ser. No. 10/582,304, filed December 16, 2008, 3 pages
	219	U.S. EXAMINER ANNE GUSSOW, USPTO Non-Final Office Action in U.S. App. Ser. No. 10/582,304, mailed April 1, 2009, 38 pages
	220	FISH & RICHARDSON P.C., Amendment in Reply to Office Action dated April 1, 2009 in U.S. App. Ser. No. 10/582,304, filed June 30, 2009, 15 pages
	221	U.S. EXAMINER ANNE GUSSOW, USPTO Non-Final Office Action in U.S. App. Ser. No. 10/582,304, mailed September 15, 2009, 22 pages
	222	JAPANESE PATENT OFFICE, International Search Report for App. Ser. No. PCT/JP2004/018501, mailed March 29, 2005, 2 pages
	223	JAPANESE EXAMINER YOSHIKO KUWAHARA, International Preliminary Report on Patentability for App. Ser. No. PCT/JP2004/018501, dated November 4, 2005, 7 pages
	224	EPO EXAMINER HELENA DOMINGUES, European Search Report for App. Ser. No. EP 04 82 0311, dated January 28, 2009, 4 pages
↓	225	JAPANESE PATENT OFFICE, International Search Report for App. Ser. No. PCT/JP2004/005152, mailed July 20, 2004, 2 pages

Examiner Signature  /Brad Duffy/	Date Considered  01/11/2010
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Substitute Form PTO-1449 (Modified)		U.S. Department of Commerce Patent and Trademark Office	Attorney Docket No. 14875-0164US1	Application No. 10/582,413
<b>Information Disclosure Statement by Applicant</b> (Use several sheets if necessary)  (37 CFR §1.98(b))		Applicant Toshihiko Ohtomo <i>et al.</i>		
		Filing Date October 26, 2006	Group Art Unit 1643	

<b>Other Documents (include Author, Title, Date, and Place of Publication)</b>		
Examiner Initial	Desig. ID	Document
/BD/	226	JAPANESE PATENT OFFICE, International Preliminary Report on Patentability for App. Ser. No. PCT/JP2004/005152, dated February 14, 2005, 6 pages
	227	EPO EXAMINER WIEBKE BERNHARDT, European Search Report for App. Ser. No. EP 04 72 6750, dated February 4, 2008, 3 pages
	228	U.S. EXAMINER BRADLEY DUFFY, USPTO Non-Final Office Action in U.S. App. Ser. No. 11/547,747, mailed June 1, 2009, 41 pages
	229	U.S. EXAMINER ELLY GERALD STOICA, USPTO Restriction Requirement in U.S. App. Ser. No. 11/913,229, mailed July 8, 2009, 6 pages
	230	FISH & RICHARDSON P.C., Response to Restriction Requirement dated July 8, 2009 in U.S. App. Ser. No. 11/913,229, filed August 4, 2009, 1 page
	231	JAPANESE PATENT OFFICE, International Search Report for App. Ser. No. PCT/JP2006/309890, mailed July 18, 2006, 2 pages
	232	JAPANESE EXAMINER MASASHI HONDA, International Preliminary Report on Patentability for App. Ser. No. PCT/JP2006/309890, dated November 19, 2006, 5 pages
	233	EPO EXAMINER TERESA SOMMERFELD, European Search Report for App. Ser. No. EP 06 74 6578, dated June 25, 2009, 2 pages
	234	U.S. EXAMINER LYNN ANNE BRISTOL, USPTO Restriction Requirement in U.S. App. Ser. No. 10/582,654, mailed May 26, 2009, 9 pages
	235	KLARQUIST SPARKMAN, LLP Response to Restriction Requirement dated May 26, 2009 in U.S. App. Ser. No. 10/582,654, filed June 23, 2009, 2 pages
	236	U.S. EXAMINER LYNN ANNE BRISTOL, USPTO Office Action in U.S. App. Ser. No. 10/582,654, mailed September 1, 2009, 39 pages
	237	U.S. EXAMINER DAVID J. BLANCHARD, USPTO Restriction Requirement in U.S. App. Ser. No. 10/399,518, mailed November 25, 2005, 9 pages
	238	FOLEY & LARDNER LLP, Response to Restriction Requirement dated November 25, 2005 in U.S. App. Ser. No. 10/399,518, filed December 23, 2005, 3 pages
	239	U.S. EXAMINER DAVID J. BLANCHARD, USPTO Non-Final Office Action in U.S. App. Ser. No. 10/399,518, mailed March 27, 2006, 38 pages
	240	FOLEY & LARDNER LLP, Amendment in Reply to Action dated March 27, 2006 in U.S. App. Ser. No. 10/399,518, filed September 26, 2006, 26 pages
	241	FOLEY & LARDNER LLP, Supplemental Amendment in Reply to Action dated March 27, 2006 in U.S. App. Ser. No. 10/399,518, filed October 11, 2006, 11 pages
	242	FOLEY & LARDNER LLP, Supplemental Amendment in Reply to Action dated March 27, 2006 in U.S. App. Ser. No. 10/399,518, filed October 13, 2006, 11 pages
	243	U.S. EXAMINER DAVID J. BLANCHARD, USPTO Non-Final Office Action in U.S. App. Ser. No. 10/399,518, mailed December 28, 2006, 29 pages
	244	FOLEY & LARDNER LLP, Amendment in Reply to Action dated December 28, 2006 in U.S. App. Ser. No. 10/399,518, filed May 3, 2007, 22 pages
	245	U.S. EXAMINER DAVID J. BLANCHARD, USPTO Final Office Action in U.S. App. Ser. No. 10/399,518, mailed June 7, 2007, 13 pages
	246	FOLEY & LARDNER LLP, Amendment in Reply to Action dated June 7, 2007 in U.S. App. Ser. No. 10/399,518, filed September 7, 2007, 9 pages

Examiner Signature  /Brad Duffy/	Date Considered  01/11/2010
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney Docket No. 14875-0164US1	Application No. 10/582,413
<b>Information Disclosure Statement by Applicant</b> (Use several sheets if necessary)  (37 CFR §1.98(b))		Applicant Toshihiko Ohtomo <i>et al.</i>	
		Filing Date October 26, 2006	Group Art Unit 1643

<b>Other Documents (include Author, Title, Date, and Place of Publication)</b>		
Examiner Initial	Desig. ID	Document
/BD/	247	U.S. EXAMINER DAVID J. BLANCHARD, Advisory Action in U.S. App. Ser. No. 10/399,518, mailed September 27, 2007, 5 pages
	248	U.S. EXAMINER DAVID J. BLANCHARD, Interview Summary in U.S. App. Ser. No. 10/399,518, mailed November 13, 2007, 3 pages
	249	U.S. EXAMINER DAVID J. BLANCHARD, USPTO Non-Final Office Action in U.S. App. Ser. No. 10/399,518, mailed January 31, 2008, 14 pages
	250	FOLEY & LARDNER LLP, Amendment in Reply to Action dated January 31, 2008 in U.S. App. Ser. No. 10/399,518, filed April 30, 2008, 7 pages
	251	U.S. EXAMINER DAVID J. BLANCHARD, USPTO Final Office Action in U.S. App. Ser. No. 10/399,518, mailed August 4, 2008, 8 pages
	252	U.S. EXAMINER DAVID J. BLANCHARD, Advisory Action in U.S. App. Ser. No. 10/399,518, mailed November 7, 2008, 3 pages
	253	FOLEY & LARDNER LLP, Amendment in Reply to Action dated November 7, 2008 in U.S. App. Ser. No. 10/399,518, filed October 22, 2008, 8 pages
	254	U.S. EXAMINER DAVID J. BLANCHARD, USPTO Non-Final Office Action in U.S. App. Ser. No. 10/399,518, mailed February 17, 2009, 12 pages
	255	FOLEY & LARDNER LLP, Amendment in Reply to Action dated February 17, 2009 in U.S. App. Ser. No. 10/399,518, filed May 18, 2009, 26 pages
	256	JAPANESE PATENT OFFICE, International Search Report for App. Ser. No. PCT/JP2004/018493, mailed March 22, 2005, 2 pages
	257	JAPANESE PATENT OFFICE, International Preliminary Report on Patentability for App. Ser. No. PCT/JP2004/018493, dated December 20, 2005, 7 pages
	258	EPO EXAMINER INGE KALSNER, European Search Report for App. Ser. No. EP 04 82 0305, dated October 6, 2008, 3 pages
	259	U.S. EXAMINER DAVID J. BLANCHARD, USPTO Final Office Action in U.S. App. Ser. No. 10/399,518, mailed September 11, 2009, 24 pages
	260	U.S. EXAMINER LYNN ANNE BRISTOL, USPTO Restriction Requirement in U.S. App. Ser. No. 10/257,864, mailed February 1, 2006, 14 pages
	261	U.S. EXAMINER PENSEE T. DO, USPTO Restriction Requirement in U.S. App. Ser. No. 10/582,176, mailed October 19, 2009, 6 pages
	262	FISH & RICHARDSON P.C., Response to Restriction Requirement dated October 19, 2009 in U.S. App. Ser. No. 10/582,176, filed November 4, 2009, 1 page
↓	263	U.S. EXAMINER ELLY GERALD STOICA, USPTO Non-Final Office Action in U.S. App. Ser. No. 11/913,229, mailed November 3, 2009, 40 pages

Examiner Signature /Brad Duffy/	Date Considered 01/11/2010
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	